Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial

Hypertension

Volumn 56, Issue 5, 2010, Pages 824-830

  Bakris, George L ^a   Lindholm, Lars H ^b   Black, Henry R ^c   Krum, Henry ^d   Linas, Stuart ^e   Linseman, Jennifer V ^f   Arterburn, Sarah ^f   Sager, Philip ^f   Weber, Michael ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c NEW YORK UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

^e DENVER HEALTH MEDICAL CENTER   (United States)

^f GILEAD SCIENCES   (United States)

^g SUNY Downstate Medical Center   (United States)

Author keywords

endothelin; endothelin antagonist; hypertension; resistant hypertension

Indexed keywords

ACETYLSALICYLIC ACID; DARUSENTAN; GUANFACINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SITING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA; AGED; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; GUANFACINE; HUMANS; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PHENYLPROPIONATES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 78149244260     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.156976     Document Type: Article

References (19)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart Lung, and Blood Institute; and National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High blood Pressure. Hypertension. 2003;42:1206-1252.
2. Mancia G, DeBacker G, Dominiczak A, for the Taskforce for the Management of Arterial Hypertension. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
3. Calhoun DA, Jones D, Trextor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Flakner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
4. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749-1757.
5. Gradman AH, Basile JN, Carter BL, Bakris GL, for the American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:42-50.
6. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
7. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR, for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
8. deSouza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152.
9. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effects of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.
10. Nakov R, Pfarr E, Eberle S, on behalf of the HEAT Investigators. Darusentan: an effective endothelin receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15:583-589.
11. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;374:1423-1431.
12. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JV, Van Lente F, for the Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
13. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Philips RA, Toto RD, Middleton JP, Rostand SG, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA. 2002;288:2421-2431.
14. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53:20-27.
15. Seedat YK. Guanfacine alone and in combination therapy in the treatment of moderate and severe hypertension. Chest. 1983;83(suppl): 403-404.
16. Jerie P. Long-term evaluations of therapeutic efficacy and safety of guanfacine. Am J Cardiol. 1986;57:55E-59E.
17. Weber MA. Clinical pharmacology of centrally acting antihypertensive agents. J Clin Pharmacol. 1989;29:598-602.
18. Fillingim JM, Blackshear JL, Strauss A, Strauss M. Guanfacine as monotherapy for systemic hypertension. Am J Cardiol. 1986;57:50E-54E.
19. Keenan RE, Black PL, Freudenburg JC, Hill JA, Holmburg CE, Reitbrock MJ, Sullivan MJ, Thompson MT, Wright DL. Usefulness of low dose guanfacine, once a day, for 24-hour control of essential hypertension. Am J Cardiol. 1986;57:38E-42E.